Brett T Staahl

20220220508, Jul 14, 2022

Dec 3, 2021

17/542219

- Alameda CA, US
Sean HIGGINS - Alameda CA, US
Hannah SPINNER - Boston MA, US
Sarah DENNY - San Francisco CA, US
Brett T. STAAHL - Tiburon CA, US
Kian TAYLOR - Atlanta GA, US
Katherine BANEY - Berkeley CA, US
Isabel COLIN - Oakland CA, US
Maroof ADIL - Davis CA, US

C12N 15/90
C12N 9/22
C12N 15/11
C12N 15/86

Provided herein are engineered CasX systems and components thereof, including variant CasX proteins and variant guide nucleic acids (gNAs). The variant CasX proteins and variant gNAs of the disclosure display at least one improved characteristic when compared to a reference CasX protein or reference gNA of the disclosure. In some instances, the variants have one or more improved CasX ribonucleoprotein complex functions. Also provided are methods of making and using said variants.

20230081117, Mar 16, 2023

Sep 9, 2020

17/641404

- Alameda CA, US
Sean HIGGINS - Alameda CA, US
Hannah SPINNER - Boston MA, US
Sarah DENNY - San Francisco CA, US
Brett T. STAAHL - Tiburon CA, US
Kian TAYLOR - Atlanta GA, US
Katherine BANEY - Berkeley CA, US
Isabel COLIN - Oakland CA, US
Maroof ADIL - Davis CA, US
Cole URNES - Los Alamitos CA, US

A61K 39/00
C12N 9/22
C12N 15/11
C07K 14/725
C07K 14/705
C07K 14/715
A61K 48/00
A61K 45/06

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and/or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.

20230054437, Feb 23, 2023

Jan 10, 2022

17/572208

- Alameda CA, US
Sean HIGGINS - Alameda CA, US
Isabel COLIN - Oakland CA, US
Sarah DENNY - San Francisco CA, US
Brett T. STAAHL - Tiburon CA, US
Benjamin OAKES - El Cerrito CA, US
Angus SIDORE - Oakland CA, US
Suraj MAKHIJA - San Francisco CA, US

C12N 15/10
C12N 9/22
C12N 15/113
C12N 15/85

Provided herein are engineered Class 2, Type V nucleases and guide RNAs useful for the editing of target nucleic acids. Also provided are methods of making and using such variants to modify nucleic acids.

20230032369, Feb 2, 2023

May 31, 2022

17/829206

- Alameda CA, US
Sean HIGGINS - Alameda CA, US
Hannah SPINNER - Boston MA, US
Sarah DENNY - San Francisco CA, US
Brett T. STAAHL - Tiburon CA, US
Kian TAYLOR - Atlanta GA, US
Katherine BANEY - Berkeley CA, US
Isabel COLIN - Oakland CA, US
Maroof ADIL - Davis CA, US
Cole URNES - Los Angeles CA, US

C12N 9/22
C12N 15/86

Provided herein are CRISPR:guide systems comprising Class 2 Type V polypeptides (e.g. CasX:gNA systems comprising CasX polypeptides), guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a HTT gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the huntingtin protein. Also provided are methods of using such systems to modify cells having such mutations and utility in methods of treatment of a subject with a HTT-related disease, such as Huntington's disease.

20230033866, Feb 2, 2023

Dec 4, 2020

17/780945

- Alameda CA, US
Hannah SPINNER - Boston MA, US
Sarah DENNY - San Francisco CA, US
Brett T. STAAHL - Tiburon CA, US
Kian TAYLOR - Atlanta GA, US
Katherine BANEY - Berkeley CA, US
Isabel COLIN - Oakland CA, US
Maroof ADIL - Davis CA, US
Cole URNES - Los Alamitos CA, US
Sean HIGGINS - Alameda CA, US

A61K 48/00
C12N 9/22
C12N 15/11
C07K 14/705
A61P 27/02
C12N 15/86

Provided herein are Class 2 Type V CRISPR:gNA systems comprising Class 2 Type V CRISPR polypeptides (e.g. CasX), guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a RHO gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the rhodopsin protein. Also provided are methods of using such systems to modify cells having such mutations and utility in methods of treatment of a subject with a RHO-related disease, such as retinitis pigmentosa.

20200115688, Apr 16, 2020

Jul 31, 2018

16/628114

- Oakland CA, US
Brett T. Staahl - San Francisco CA, US
Jennifer Sabo - Berkeley CA, US

C12N 9/22
C12N 15/90
A61K 47/18

The present disclosure provides a composition comprising an RNA-guided endonuclease and an agent that decreases the acidity of an endosome. The present disclosure provides a composition comprising: a) a ribonucleoprotein (RNP) complex comprising: i) an RNA-guided endonuclease; and ii) a guide RNA comprising a segment that binds to the RNA-guided endonuclease and a segment that binds to a target nucleic acid; and b) an agent that decreases the acidity of an endosome. The present disclosure provides methods of binding a target nucleic acid in a eukaryotic cell; and methods of genetically modifying a target eukaryotic cell.

20180044700, Feb 15, 2018

Sep 1, 2015

15/502720

- Oakland CA, US
Steven LIN - Albany CA, US
Brett T. STAAHL - San Francisco CA, US

C12N 15/90

The present disclosure provides compositions and methods of site-specific modification of a target DNA, or a protein associated with a target DNA, in a eukaryotic cell. The present disclosure provides methods of binding a target DNA in a eukaryotic cell.